Limits...
A case of advanced malignant pleural mesothelioma treatment with chemotherapy and photodynamic therapy.

Ryu JW, Kim YS - Tuberc Respir Dis (Seoul) (2015)

Bottom Line: Our patient received chemotherapy using pemetrexed/cisplatin.Afterwards, he received a single PDT treatment and then later took chemotherapy using gemcitabine/cisplatin.The patient showed a survival time of 27 months, which is longer than median survival time in advanced MPM patients.

View Article: PubMed Central - PubMed

Affiliation: Department of Thoracic and Cardiovascular Surgery, Dankook University College of Medicine, Cheonan, Korea.

ABSTRACT
Malignant pleural mesothelioma (MPM) is an aggressive, treatment-resistant, and generally fatal disease. A 68-year-old male who was diagnosed with MPM at another hospital came to our hospital with dyspnea. We advised him to take combination chemotherapy but he refused to take the treatment. That was because he had already received chemotherapy with supportive care at another hospital but his condition worsened. Thus, we recommended photodynamic therapy (PDT) to deal with the dyspnea and MPM. After PDT, the dyspnea improved and the patient then decided to take the combination chemotherapy. Our patient received chemotherapy using pemetrexed/cisplatin. Afterwards, he received a single PDT treatment and then later took chemotherapy using gemcitabine/cisplatin. The patient showed a survival time of 27 months, which is longer than median survival time in advanced MPM patients. Further research and clinical trials are needed to demonstrate any synergistic effect between the combination chemotherapy and PDT.

No MeSH data available.


Related in: MedlinePlus

(A) This chest radiograph shows the initial findings before photodynamic therapy at our hospital. (B) After 1 week of photodynamic therapy, this chest radiograph shows a slightly decreased extent of consolidation in the right lower chest.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4311034&req=5

Figure 4: (A) This chest radiograph shows the initial findings before photodynamic therapy at our hospital. (B) After 1 week of photodynamic therapy, this chest radiograph shows a slightly decreased extent of consolidation in the right lower chest.

Mentions: Pemetrexed and cisplatin combination chemotherapy was performed. Pemetrexed 500 mg/m2 with cisplatin 60 mg/m2 were administered once every 3 weeks. The patient was discharged with better condition of dyspnea (Figure 4A, B). After six cycles of pemetrexed/cisplatin combination chemotherapy, the tumor volume had not shown significant interval change. But, he remained relatively stable for 6 months after multimodality therapy. At 7 months of the multimodality treatment, dyspnea was aggravated and progression of disease was shown on the chest CT. So the PDT single treatment was carried out in the same way and the symptom improved. Although significant decreased in the mass volume was not seen, his symptom improved and he remained stable without further treatment during the 9 months after the second PDT. Ten months after the second PDT, dyspnea became worse again, and progression of disease was shown on the chest CT. The third PDT was intended but failed to be performed due to the patient's financial reason. Instead, the patient took combination chemotherapy. The patient was treated with gemcitabine 1,000 mg/m2 on days 1 and 8, and cisplatin 60 mg/m2 on day 1. This chemotherapy regimen was repeated once every 3 weeks. However dramatic response was not shown. He died 27 months after initial diagnosis with MPM.


A case of advanced malignant pleural mesothelioma treatment with chemotherapy and photodynamic therapy.

Ryu JW, Kim YS - Tuberc Respir Dis (Seoul) (2015)

(A) This chest radiograph shows the initial findings before photodynamic therapy at our hospital. (B) After 1 week of photodynamic therapy, this chest radiograph shows a slightly decreased extent of consolidation in the right lower chest.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4311034&req=5

Figure 4: (A) This chest radiograph shows the initial findings before photodynamic therapy at our hospital. (B) After 1 week of photodynamic therapy, this chest radiograph shows a slightly decreased extent of consolidation in the right lower chest.
Mentions: Pemetrexed and cisplatin combination chemotherapy was performed. Pemetrexed 500 mg/m2 with cisplatin 60 mg/m2 were administered once every 3 weeks. The patient was discharged with better condition of dyspnea (Figure 4A, B). After six cycles of pemetrexed/cisplatin combination chemotherapy, the tumor volume had not shown significant interval change. But, he remained relatively stable for 6 months after multimodality therapy. At 7 months of the multimodality treatment, dyspnea was aggravated and progression of disease was shown on the chest CT. So the PDT single treatment was carried out in the same way and the symptom improved. Although significant decreased in the mass volume was not seen, his symptom improved and he remained stable without further treatment during the 9 months after the second PDT. Ten months after the second PDT, dyspnea became worse again, and progression of disease was shown on the chest CT. The third PDT was intended but failed to be performed due to the patient's financial reason. Instead, the patient took combination chemotherapy. The patient was treated with gemcitabine 1,000 mg/m2 on days 1 and 8, and cisplatin 60 mg/m2 on day 1. This chemotherapy regimen was repeated once every 3 weeks. However dramatic response was not shown. He died 27 months after initial diagnosis with MPM.

Bottom Line: Our patient received chemotherapy using pemetrexed/cisplatin.Afterwards, he received a single PDT treatment and then later took chemotherapy using gemcitabine/cisplatin.The patient showed a survival time of 27 months, which is longer than median survival time in advanced MPM patients.

View Article: PubMed Central - PubMed

Affiliation: Department of Thoracic and Cardiovascular Surgery, Dankook University College of Medicine, Cheonan, Korea.

ABSTRACT
Malignant pleural mesothelioma (MPM) is an aggressive, treatment-resistant, and generally fatal disease. A 68-year-old male who was diagnosed with MPM at another hospital came to our hospital with dyspnea. We advised him to take combination chemotherapy but he refused to take the treatment. That was because he had already received chemotherapy with supportive care at another hospital but his condition worsened. Thus, we recommended photodynamic therapy (PDT) to deal with the dyspnea and MPM. After PDT, the dyspnea improved and the patient then decided to take the combination chemotherapy. Our patient received chemotherapy using pemetrexed/cisplatin. Afterwards, he received a single PDT treatment and then later took chemotherapy using gemcitabine/cisplatin. The patient showed a survival time of 27 months, which is longer than median survival time in advanced MPM patients. Further research and clinical trials are needed to demonstrate any synergistic effect between the combination chemotherapy and PDT.

No MeSH data available.


Related in: MedlinePlus